Investing Profile

Stephen Knight

InvestorVC

President & Managing Partner at F-Prime Capital

fprimecapital.com/people/step...Cambridge, Massachusetts

Your Intro Paths to Stephen Knight

Signal uses Gmail to reveal intro paths. Email content is never read.

Networks Stephen is a member of

Columbia University in the City of New York Network

348 CONNECTIONS

Columbia University Network

252 CONNECTIONS

Arthur D. Little Network

22 CONNECTIONS

Find Stephen Knight on

Current Investing Position

F-Prime Capital Partners

Investment Range

$100K - $10.0M

Sweet Spot

$5.0M

Investments On Record

Stephen Knight is on these Sector & Stage Rankings

BioTech (Series B)Pharmaceuticals (Series B)BioTech (Series A)Pharmaceuticals (Series A)Health IT (Series A)Health & Hospital Services (Series B)Health & Hospital Services (Series A)Boston / New England Health IT (Series B)

Stephen Knight's Investments On Record (9)

Company	StageDateRound Size	Total Raised
Paradigm	Series BDec 2025$78M Series AJan 2023$200M	$320M
Co-investors: David Schenkein (GV (Google Ventures)), Elena Viboch (General Catalyst), Hemant Taneja (General Catalyst), Max Rimpel (Index Ventures), Niko Bonatsos (General Catalyst), Bilal Zuberi (Lux Capital), Brett Cook (F-Prime Capital Partners), Ramnik Arora (Original Capital), Eoghan McCabe (Spark-Local, Inc), Jay Markowitz (ARCH Venture Partners), Robert Nelsen (ARCH Venture Partners), Alaa Halawa (Vir Biotechnology, Inc.), Justin Kao (DFJ Growth), Jared Friedman (Y Combinator), Scott Belsky (A24), Balaji Srinivasan, Karim Atiyeh, Arash Ferdowsi
Ensoma	Series UnknownSep 2025$53M Series BJan 2023$85M Series AFeb 2021$70M	$260M
Co-investors: Kush Parmar (5am Ventures), Mark Chin (Jmi Equity), Kouki Harasaki (M12 - Microsoft's Venture Fund)
Atalanta Therapeutics	Series BJan 2025$97M Series AJan 2021$110M	$210M
Co-investors: Jessica Alston (F-Prime Capital Partners), Stacie Weninger (F-Prime Capital Partners), Jason P. Hafler (Sanofi Ventures), Niall O’Donnell (RiverVest Venture Partners)
Quantum Circuits	Series BMay 2024$60M	$78M
Co-investors: Bill Coughran (Sequoia Capital), Brendan Dickinson (Canaan Partners), Eugene Chiu (IQT), Corey Ritter (ARCH Venture Partners)
Genomics	Series CJan 2024$45M Series UnknownMar 2021$30M Series BDec 2018$9M	$84M
Co-investors: Jim Tananbaum (Foresite Capital Management)
Aerium Therapeutics	Series AMar 2022
Co-investors: Michael Powell (Omega Funds), Vincent Ossipow (Omega Funds)
Leyden Labs	Series BJan 2022$140M Series AMar 2021$47M	$300M
Co-investors: David Schenkein (GV (Google Ventures)), Hermann Hauser (Amadeus Capital Partners), Nisa Leung (Qiming Venture Partners), Brook Byers (Moving Capital), Jeffrey Bird (Bluebird Ventures), Eli Casdin (Casdin Capital, LLC)
Prime Medicine	Series BJul 2021$200M Series AOct 2019$120M	$320M
Co-investors: David Schenkein (GV (Google Ventures)), Neil Sirni (Proximity Ventures), Stephen Francis (MONTAJ), Robert Nelsen (ARCH Venture Partners)

Stephen Knight's Experience

Junior Researcher AT&T Bell LaboratoriesPresent

Researcher AT&T Bell LaboratoriesPresent

Consultant Arthur D. LittlePresent

President, COO EPIX PharmaceuticalsPresent

President & Senior Managing Partner AT&T Bell LaboratoriesPresent

President & Managing Partner F-Prime Capital (formerly Fidelity Biosciences)Present

Stephen Knight's Education

Columbia University BS Biology

Columbia University in the City of New York BS Biology

Investors who invest with Stephen Knight

Scouts & Angels Affiliated With Stephen Knight